{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7536,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "key_takeaways",
      "function": "present_solution",
      "notes": "The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/13",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/14",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/15",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/16",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "other",
      "function": "present_solution",
      "notes": "Includes comparative data points for CAR-T characteristics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/17",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "other",
      "function": "analyze_data",
      "notes": "The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/18",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 9,
          "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Solution & Approach",
          "beatSlug": "consultants-gambit-solution-approach",
          "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/19",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/20",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/21",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/22",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/23",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/24",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/25",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes a footnote citing FDA approval precedents for similar single-arm studies.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/26",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-26",
      "loopMatches": [
        {
          "to": 29,
          "from": 26,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645",
          "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts",
          "position": 1,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a before-and-after visual comparison to illustrate market expansion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/27",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-27",
      "loopMatches": [
        {
          "to": 29,
          "from": 26,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645",
          "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts",
          "position": 1,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "Includes detailed source citations in the footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/28",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-28",
      "loopMatches": [
        {
          "to": 29,
          "from": 26,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645",
          "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts",
          "position": 1,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a two-column layout to separate milestones for two distinct drug programs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/29",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-29",
      "loopMatches": [
        {
          "to": 29,
          "from": 26,
          "name": "Why Now",
          "slug": "15-why-now",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "matchId": "f780d3f4-ce52-46e0-bb27-b6f0acceb645",
          "evidence": "Slides 26-29 discuss the clinical development plan and upcoming catalysts",
          "position": 1,
          "objective": "Why is now the right time for NXC-201?",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "confidence": 0.6,
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "roadmap",
      "function": "present_solution",
      "notes": "The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/30",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-30",
      "loopMatches": [
        {
          "to": 32,
          "from": 30,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26",
          "evidence": "Slides 30-32 discuss the market opportunity for NXC-201",
          "position": 2,
          "objective": "What is the potential for NXC-201 in large markets?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/31",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-31",
      "loopMatches": [
        {
          "to": 32,
          "from": 30,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26",
          "evidence": "Slides 30-32 discuss the market opportunity for NXC-201",
          "position": 2,
          "objective": "What is the potential for NXC-201 in large markets?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a wave-like visual to represent market segments and their associated dollar values.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/32",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-32",
      "loopMatches": [
        {
          "to": 32,
          "from": 30,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26",
          "evidence": "Slides 30-32 discuss the market opportunity for NXC-201",
          "position": 2,
          "objective": "What is the potential for NXC-201 in large markets?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/33",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/34",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/35",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-35",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/36",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-36",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 19,
          "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "other",
      "function": "analyze_data",
      "notes": "The chart illustrates deepening responses in patients treated with NXC-201 over time.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/37",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/38",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": "The slide uses a numbered list format to present clinical milestones and market opportunities.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/39",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "appendix",
      "function": "appendix",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/40",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Uses icon-based visualization to represent market expansion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/41",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide uses a process flow diagram to illustrate dose escalation steps.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/42",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}